SKSvend Kjaer

Svend Kjaer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svend Kjaer has a total of 536 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EXPERT: A practical and forward-looking guide to capturing protein expression and purification metadata to develop machine learning models

    by Christopher D.O. Cooper, Evgeny Tankhilevich, Kim Remans, Ahmed El Marjou, Aled M. Edwards, Andrew R. Leach, Andrew Quigley, Anja Schütz, Anne Zemella, Ario de Marco, et al.

  • Membrane lipid composition and endocytosis modulate Wingless release from secreting cells

    by Ines Alvarez Rodrigo, David Willnow, Cyrille Alexandre, Claire Lebarbenchon, Annabel Borg, Heather Findlay, Maya Hoad Leftley, Ikram Arahouan, Yuguang Zhao, Florencia di Pietro, et al.

    BioStudies – one package for all the data supporting a study

  • Open Access

    Coupling dead cell recognition to Fcγ receptors augments anticancer immunity

    by Tomás Castro-Dopico, Cécile Piot, Michael D. Buck, Lucía Gandullo-Sánchez, Kok Haw Jonathan Lim, Gerone A. Gonzales, Nikita Rosendahl, Oliver Schulz, William Stainier, Brian Vash, et al.

    Type 1 conventional dendritic cells (cDC1s) are key antigen-presenting cells (APCs) for cross-priming of CD8 + T cells against cancer. They can capture and cross-present dead cell antigens via DNGR-1 (CLEC9A), a receptor for F-actin exposed on cell corpses. However, cDC1s are scarce in human and murine tumors, and this restricts anticancer immunity. We show that abundant tumor-associated APCs, including cDC2s and monocyte-derived cells, can be redirected to internalize necrotic debris and cross-present associated antigens by a variety of reagents that bridge F-actin to Fcγ receptors (FcγRs), including an Fc–DNGR-1 fusion protein and an anti-F-actin antibody. In vivo, Fc–DNGR-1 accumulates in necrotic tumor areas and highlights their proximity to intratumoral FcγR + APCs. In mouse cancer models, F-actin–FcγR bridging enhances tumor control and synergizes with cytotoxic chemotherapy or radiotherapy. Thus, nonspecialized APCs can be harnessed for cross-presentation of necrotic tumor antigens, and F-actin–FcγR bridging constitutes a strategy to potentiate anticancer immunity.


  • Open Access

    The antipsychotic drug clozapine suppresses autoimmunity driving psychosis-like behavior in mice

    by Le He, Harriet Feldman, Timothy Nguyen, Marion Bosc, Vasishta Polisetty, Orla Kriel, Antonia Landwehr, Annabel Borg, Fernanda Teixera Subtil, Mohammadparsa Khakpour, et al.

    Antipsychotic drugs are the first-line treatment for psychosis yet their mechanism of action remains poorly understood, largely due to the challenge to faithfully model psychosis preclinically. Here, we focus on the emerging concept that psychosis can be caused by brain autoimmunity and present a novel mouse model of anti-N-methyl-D-aspartate-receptor (anti-NMDAR) encephalitis, a condition that manifests with psychosis and autoantibodies against the NMDAR. We devised a new mRNA-based approach to immunize mice against the NMDAR. Immunized mice developed psychosis-like behaviors that were caused by anti-NMDAR autoantibodies leading to phagocytosis of NMDARs by brain micro-glia. The antipsychotic drug clozapine rescued psychosis-like behaviors and, remarkably, reduced anti-NMDAR autoantibody levels and antibody-mediated phagocytosis of NMDARs. The immunomodulato-ry effects of clozapine were confirmed in a mouse model of systemic lupus erythematosus. Our results demonstrate that clozapine suppresses autoimmunity driving psychosis-like behaviors, raising the possibility that immunomodulation contributes to antipsychotic drug action.


  • Open Access

    Hydrogen/deuterium exchange mass spectrometry analysis of ribosome-nascent chain complexes to study protein biogenesis at the peptide level

    by Alžběta Roeselová, Aleksandra Pajak, Thomas E. Wales, Grant A. Pellowe, Svend Kjær, John R. Engen, David Balchin

    Nascent proteins begin to fold during their synthesis, while still attached to the ribosome. The dynamic nature of ribosome–nascent chain complexes (RNCs) poses a challenge for conventional structural biology approaches, limiting our understanding of dynamic cotranslational events. Hydrogen–deuterium exchange mass spectrometry (HDX-MS) is a powerful label-free technique for studying the conformational equilibria and refolding of full-length proteins with peptide resolution. However, the large size of the ribosome and the need for stable, highly homogeneous samples have hindered the application of HDX-MS to RNCs. Here we present a strategy for analysing conformational dynamics and interactors of Escherichia coli RNCs using HDX-MS. High-quality RNCs are obtained through the gentle lysis of high-density cultures expressing uniformly stalled ribosomes, followed by ultracentrifugation and tag-based affinity purification. Peptide-resolution information on protein conformational dynamics is obtained by pulse deuterium labeling, quenching with an RNA-compatible low pH buffer and offline digestion with pepsin. Extensive data analysis with use of specific internal controls allows for the confident assignment of mass spectra to specific peptides, ensuring good coverage of the nascent chain and ribosomal proteins. This method provides a valuable complement to existing structural techniques such as cryo-electron microscopy and nuclear magnetic resonance, and enables detailed characterization of large, partially structured nascent chains and their interactions with the ribosomal proteins and molecular chaperones. The protocol takes 1–3 months, from sample preparation and data acquisition to data analysis, and requires standard expertise in cloning and protein purification and intermediate expertise in HDX-MS.


  • Open Access

    Convergent Lead Discovery Strategies Yield Covalent and Non-covalent Inhibitors of Human UDP-Galactose-4-Epimerase

    by William Browne, Jonathan Pettinger, Teresa Weckwerth, Andrew Purkiss, Sing Hei Lok, Louisa Penicaut, Roksana Ogrodowicz, Raveena Morar, Simone Kunzelmann, Chloe Roustan, et al.

    O-GalNAc (N-acetylgalactosaminyl) glycosylation is an abundant posttranslational modification in mammalian cells. Dysregulation of O-GalNAc glycosylation is implicated in cancer metastasis and immune evasion; however, our mechanistic understanding remains limited due to the lack of small molecule tools. O-GalNAc biosynthesis depends heavily on the availability of UDP-GalNAc that is biosynthesised by the cytosolic enzyme UDP-galactose-4-epimerase (GalE). Knockout studies have demonstrated that loss of GalE severely impairs O-GalNAc glycosylation, positioning GalE as a promising enzymatic therapeutic target in oncology. Here, we present an efficient, convergent workflow that combines both covalent and high-throughput crystallographic non-covalent fragment screening with structure-based design to identify GalE inhibitors. Using these strategies, we discovered a ligandable pocket adjacent to a reactive tyrosine, enabling the development of a potent, “beyond cysteine” covalent inhibitor based on a sulfonyl fluoride warhead. Structurally-enabled fragment screening methodologies yielded nanomolar non-covalent as well as covalent binders within no more than 22 elaborated compounds. Our work demonstrates efficient synergism in next-generation delivery of chemical matter for GalE inhibition, with the broader potential for targeting non-cysteine residues in chemical biology and therapeutic applications.

  • Open Access

    The human ribosome modulates multidomain protein biogenesis by delaying cotranslational domain docking

    by Grant A. Pellowe, Tomas B. Voisin, Laura Karpauskaite, Sarah L. Maslen, Alžběta Roeselová, J. Mark Skehel, Chloe Roustan, Roger George, Andrea Nans, Svend Kjær, et al.

    Proteins with multiple domains are intrinsically prone to misfold, yet fold efficiently during their synthesis on the ribosome. This is especially important in eukaryotes, where multidomain proteins predominate. Here we sought to understand how multidomain protein folding is modulated by the eukaryotic ribosome. We used hydrogen–deuterium exchange mass spectrometry and cryo-electron microscopy to characterize the structure and dynamics of partially synthesized intermediates of a model multidomain protein. We find that nascent subdomains fold progressively during synthesis on the human ribosome, templated by interactions across domain interfaces. The conformational ensemble of the nascent chain is tuned by its unstructured C-terminal segments, which keep interfaces between folded domains in dynamic equilibrium until translation termination. This contrasts with the bacterial ribosome, on which domain interfaces form early and remain stable during synthesis. Delayed domain docking may avoid interdomain misfolding to promote the maturation of multidomain proteins in eukaryotes.


  • Open Access

    Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation

    by Lorin Adams, Phoebe Stevenson‐Leggett, Jia Le Lee, James Bazire, Giulia Dowgier, Agnieszka Hobbs, Chloë Roustan, Annabel Borg, Christine Carr, Silvia Innocentin, et al.

    Background: Influenza remains a significant threat to human and animal health. Assessing serological protection against influenza has relied upon haemagglutinin inhibition (HAI) assays, which are used to gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology studies. HAI assays were first described in the 1940s. Here, we adapt our high‐throughput live virus microneutralisation (LV‐N) assay for SARS‐CoV‐2, benchmark against HAI assays, and report serological vaccine responsiveness in a cohort of older (> 65 yo) community dwelling adults.Methods: Influenza‐specific antibody responses were assessed in 73 individuals, before and after receipt of the adjuvanted 2021–22 Northern Hemisphere quadrivalent vaccine. We performed both HAI and LV‐N assays against all four viruses represented in the vaccine [A/Cambodia/e0826360/2020 (H3N2), IVR‐215 (A/Victoria/2570/2019‐like) (H1N1)pdm09, B/Phuket/3073/2013 (B/Yamagata lineage), B/Washington/02/2019 (B/Victoria lineage)], using sera drawn before vaccination [range: d‐82 to d‐5], and days 7 [d6–10] and 181 [d156–200] after vaccination. We compared serological responses within each assay and between assays.Results: Both the traditional HAI assay and our high‐throughput live virus microneutralisation identified vaccine‐induced boosts in antibody titres. We found population‐level concordance between the two assays (Spearman's correlation coefficient range 0.49–0.88; all p ≤ 1.4 × 10−5). The improved granularity of microneutralisation was better able to estimate fold changes of responses and quantify the inhibitory effect of pre‐existing antibody.Conclusions: Our high‐throughput method offers an alternative approach to assess influenza‐specific serological responses with improved resolution, with the potential to improve the annual assessment of existing antibody landscapes, to improve new vaccine strain evaluation, and to offer a step‐change in systems vaccinology, and a facet of laboratory‐based pandemic preparedness.


  • Open Access

    The fast-evolving FIKK kinase family of Plasmodium falciparum can be inhibited by a single compound

    by Hugo Belda, David Bradley, Evangelos Christodoulou, Stephanie D. Nofal, Malgorzata Broncel, David Jones, Heledd Davies, M. Teresa Bertran, Andrew G. Purkiss, Roksana W. Ogrodowicz, et al.

    Of 250 Plasmodium species, 6 infect humans, with P. falciparum causing over 95% of 600,000 annual malaria-related deaths. Its pathology arises from host cell remodelling driven by over 400 exported parasite proteins, including the FIKK kinase family. About one million years ago, a bird-infecting Plasmodium species crossed into great apes and a single non-exported FIKK kinase gained an export element. This led to a rapid expansion into 15–21 atypical, exported Ser/Thr effector kinases. Here, using genomic and proteomic analyses, we demonstrate FIKK differentiation via changes in subcellular localization, expression timing and substrate motifs, which supports an individual important role in host–pathogen interactions. Structural data and AlphaFold2 predictions reveal fast-evolving loops in the kinase domain that probably enabled rapid functional diversification for substrate preferences. One FIKK evolved exclusive tyrosine phosphorylation, previously thought absent in Plasmodium. Despite divergence of substrate preferences, the atypical ATP binding pocket is conserved and we identified a single compound that inhibits all FIKKs. A pan-specific inhibitor could reduce resistance development and improve malaria control strategies.


  • Open Access

    Resolving chaperone-assisted protein folding on the ribosome at the peptide level

    by Thomas E. Wales, Aleksandra Pajak, Alžběta Roeselová, Santosh Shivakumaraswamy, Steven Howell, Svend Kjær, F. Ulrich Hartl, John R. Engen, David Balchin

    Protein folding in vivo begins during synthesis on the ribosome and is modulated by molecular chaperones that engage the nascent polypeptide. How these features of protein biogenesis influence the maturation pathway of nascent proteins is incompletely understood. Here, we use hydrogen–deuterium exchange mass spectrometry to define, at peptide resolution, the cotranslational chaperone-assisted folding pathway of Escherichia coli dihydrofolate reductase. The nascent polypeptide folds along an unanticipated pathway through structured intermediates not populated during refolding from denaturant. Association with the ribosome allows these intermediates to form, as otherwise destabilizing carboxy-terminal sequences remain confined in the ribosome exit tunnel. Trigger factor binds partially folded states without disrupting their structure, and the nascent chain is poised to complete folding immediately upon emergence of the C terminus from the exit tunnel. By mapping interactions between the nascent chain and ribosomal proteins, we trace the path of the emerging polypeptide during synthesis. Our work reveals new mechanisms by which cellular factors shape the conformational search for the native state.